



Supplement

Table S1. Changes in echocardiographic parameters during SGLT2i medication.

Value	N	Initial value	Mean change	P-value
IVSd (mm)	76	17.6	-0.0	0.87
LVPWd (mm)	76	14.2	+0.0	0.13
RV wall thickness (mm)	62	6.68	+0.52	0.05
LVEDV biplane (ml)	73	95.7	+8.14	0.04
LV stroke volume (ml)	70	75.8	-6.25	0.01
Cardiac output (l/min)	69	5.10	-0.50	<0.01
LVEF biplane (%)	76	51.4	-0.29	0.78
GLPS	67	-11.9	+0.97	0.55
MV E/E' mean	68	17.6	-1.40	0.03
MAPSE septal (mm)	70	7.36	-0.46	0.10
MAPSE lateral (mm)	70	8.73	-0.31	0.32
MV E max (ms)	70	0.87	-0.03	0.07
MV E' septal (cm/s)	70	4.35	+0.01	0.93
MV E' mean (cm/s)	67	5.54	-0.17	0.42
TAPSE (cm)	74	1.83	-0.27	0.14
TV S' (cm/s)	63	10.1	+0.06	0.85
TR max PG (mmHg)	67	35.4	-3.29	<0.01

Table S1: Changes in echocardiographic parameters during SGLT2i medication (all normally distributed). E: early mitral inflow velocity. E': early LV relaxation velocity. GLPS: global longitudinal peak strain. IVSd: interventricular septal wall diameter. LV: left ventricle. LVEDV: left-ventricular-end-diastolic volume. LVEF: left-ventricular-ejection fraction. LVPWd: left-ventricular posterior wall diameter. MAPSE: mitral annular plane systolic excursion. MV: mitral valve. RV: right ventricle. RVS: lateral tricuspid annulus peak systolic velocity. TAPSE: tricuspid annulus peak systolic excursion. TR max PG: maximal systolic pressure gradient across tricuspid valve. TV-S': peak systolic tissue velocity. We tested for significant differences in the normally distributed variables with the paired t-test.

Table S2. Changes in laboratory parameters during SGLT2i medication.

A) Normally distributed serological parameters	N	Initial mean	Mean change	Two-sided p
Sodium (mmol/L)	77	140.61	-1.64	<0.01
Potassium (mmol/L)	77	4.53	-0.05	0.33
Calcium (mmol/L)	77	2.34	+0.03	0.07
Chloride (mmol/L)	74	101.74	-1.27	<0.01
Phosphate (mmol/L)	77	1.19	-0.04	0.05
Serum protein (g/dL)	77	6.74	+0.09	0.15
Serum albumin (g/dL)	77	4.24	+0.01	0.77
Prealbumin (mg/dL)	36	27.27	-0.03	0.96
Total cholesterol (mg/dL)	74	173.65	-2.88	0.55
Creatinine/(mg/dL)	77	1.44	+0.09	0.06
eGFR (CKD EPI. ml/min/1.73 m ²)	77	49.89	-2.67	<0.01
Cystatin C (mg/L)	70	1.56	+0.12	<0.01
Urea (mg/dL)	77	59.30	+2.50	0.46
Uric acid (mg/dL)	77	8.04	-0.88	<0.01
ALAT (U/L)	77	22.84	-1.35	0.15
ASAT (U/L)	77	30.15	-1.51	0.08
Choline esterase (U/L)	62	6472.19	+78.31	0.49
GGT (U/L)	76	109.69	-7.15	0.51
Bilirubin (mg/dL)	70	0.78	+0.01	0.68
PTT (s)	74	27.23	+1.41	<0.01
INR	74	1.22	-0.03	0.42
Thrombocytes/nL	76	191.50	+7.94	0.19
Hematocrit (%)	76	40.23	+0.75	0.07
Hemoglobin (g/dL)	76	13.51	+0.26	0.04
Leukocytes/nL	76	7.15	+0.06	0.80

B) Non-normally distributed serological parameters	n	Before initiation median (quartiles)	After initiation median (quartiles)	p-value
NTproBNP (pg/mL)	69	2213 (933; 3661.5)	2484 (987; 4551)	0.534
C-reactive protein (mg/dL)	48	0.35 (0.17; 0.55)	0.41 (0.25; 0.94)	0.232
hsTroponinT (pg/mL)	70	41.3 (28.33; 72.43)	47.95 (28.38; 64.7)	<0.01

C) Urinalysis	n	Before initiation median (quartiles)	After initiation median (quartiles)	p-value
Erythrocytes (1/μL urine)	64	3 (1; 5)	2 (1; 4)	0.043
Leukocytes (1/μL urine)	63	3 (1; 8.25)	1.5 (1; 7)	0.443
Bacteria (1/μL urine)	61	4 (1; 24)	5 (1; 20)	0.737
Albumin/creatinine (mg/g in urine)	48	49.45 (21.6; 214.98)	51.5 (20.5; 234.65)	0.532
Protein/creatinine (mg/g in urine)	48	143 (100; 441)	155 (109; 350)	0.712

Table S2: Changes in A) normally distributed; B) non-normally distributed variables in blood serum; and C) parameters in urine (all non-normally distributed) during SGLT2i medication. ALAT: alanine transaminase. ASAT: aspartate transaminase. CKD EPI: Chronic Kidney Disease Epidemiology Collaboration estimator. eGFR: estimated glomerular filtration rate. GGT: gamma-glutamyl-transferase. Hs-TropT: highly sensitive troponinT. INR: international normalized ratio for quick values. NT-proBNP: N-terminal pro-brain-natriuretic peptide. PTT: partial thromboplastin time. A) Paired t-test or Wilcoxon signed-rank test was used, according to the nature of the data. B, C) Descriptives of these non-normally distributed variables are reported for before and after the initiation of SGLT2-inhibitor therapy. Pairwise comparisons were analyzed with the Wilcoxon paired signed rank test.